Dexcom Inc DXCM
We take great care to ensure that the data presented and summarized in this overview for DEXCOM INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DXCM
View all-
Vanguard Group Inc Valley Forge, PA49.5MShares$2.87 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY34.5MShares$2 Billion0.09% of portfolio
-
State Street Corp Boston, MA16.9MShares$979 Million0.04% of portfolio
-
Baillie Gifford & CO15.9MShares$922 Million0.84% of portfolio
-
Geode Capital Management, LLC Boston, MA11MShares$637 Million0.05% of portfolio
-
Jennison Associates LLC10.1MShares$586 Million0.4% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL8.14MShares$473 Million0.19% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL7.48MShares$434 Million0.11% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il6.78MShares$394 Million0.07% of portfolio
-
Nuveen, LLC Charlotte, NC6.34MShares$368 Million0.12% of portfolio
Latest Institutional Activity in DXCM
Top Purchases
Top Sells
About DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Insider Transactions at DXCM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2025
|
Richard Alexander Collins Director |
SELL
Open market or private sale
|
Indirect |
2,906
-7.65%
|
$171,454
$59.05 P/Share
|
|
Nov 12
2025
|
Bridgette P Heller Director |
SELL
Open market or private sale
|
Direct |
1,012
-3.61%
|
$58,696
$58.07 P/Share
|
|
Nov 10
2025
|
Richard Alexander Collins Director |
SELL
Open market or private sale
|
Indirect |
3,948
-9.41%
|
$217,140
$55.17 P/Share
|
|
Nov 10
2025
|
Jacob Steven Leach President & COO |
BUY
Open market or private purchase
|
Direct |
18,200
+2.65%
|
$1,001,000
$55.21 P/Share
|
|
Oct 24
2025
|
Euan A. Ashley Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,166
+50.0%
|
-
|
|
Sep 05
2025
|
Kyle Malady Director |
SELL
Open market or private sale
|
Direct |
667
-2.86%
|
$53,360
$80.86 P/Share
|
|
Sep 04
2025
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
1,466
-1.37%
|
$117,280
$80.0 P/Share
|
|
Sep 02
2025
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
4,824
-3.91%
|
$356,976
$74.17 P/Share
|
|
Aug 15
2025
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-0.53%
|
$40,000
$80.29 P/Share
|
|
Aug 15
2025
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
2,750
-2.56%
|
$222,750
$81.28 P/Share
|
|
Jul 28
2025
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
1,466
-1.36%
|
$129,008
$88.99 P/Share
|
|
Jul 15
2025
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
2,750
-2.43%
|
$233,750
$85.6 P/Share
|
|
Jul 15
2025
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-0.53%
|
$43,000
$86.03 P/Share
|
|
Jun 26
2025
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
1,466
-1.34%
|
$124,610
$85.06 P/Share
|
|
Jun 16
2025
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-0.52%
|
$41,000
$82.8 P/Share
|
|
Jun 16
2025
|
Mark G Foletta Director |
SELL
Open market or private sale
|
Indirect |
2,750
-4.63%
|
$228,250
$83.13 P/Share
|
|
Jun 16
2025
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Indirect |
3,672
-9.9%
|
$301,104
$82.8 P/Share
|
|
Jun 13
2025
|
Nicholas Augustinos Director |
SELL
Open market or private sale
|
Indirect |
2,618
-6.59%
|
$212,058
$81.69 P/Share
|
|
May 27
2025
|
Sadie Stern EVP, Chief HR Officer |
SELL
Open market or private sale
|
Direct |
6,184
-5.34%
|
$525,640
$85.11 P/Share
|
|
May 23
2025
|
Michael Jon Brown EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.47%
|
$840,000
$84.28 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 521K shares |
|---|---|
| Open market or private purchase | 18.2K shares |
| Bona fide gift | 16.1K shares |
| Open market or private sale | 184K shares |
|---|---|
| Bona fide gift | 16.1K shares |